ATRA (Atara Biotherapeutics) FCF Yield %: -28.32 (As of Jun. 26, 2026)


ATRA Atara Biotherapeutics Inc ATRA
31 GF Score
Price $10.14
GF Value $1.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics FCF Yield %?

Atara Biotherapeutics ATRA -3.13% 31 FCF Yield % is -28.32 as of Jun. 26, 2026. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.56 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, Atara Biotherapeutics ranks worse than 72.92% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Atara Biotherapeutics's Trailing 12-Month Free Cash Flow is $-25.88 Mil, and Market Cap is $91.36 Mil. Therefore, Atara Biotherapeutics's FCF Yield % for today is -28.32%.

The historical rank and industry rank for Atara Biotherapeutics's FCF Yield % or its related term are showing as below:

ATRA' s FCF Yield % Range Over the Past 10 Years
Min: -820.7   Med: -67.98   Max: -11.62
Current: -28.32


During the past 13 years, the highest FCF Yield % of Atara Biotherapeutics was -11.62%. The lowest was -820.70%. And the median was -67.98%.

ATRA's FCF Yield % is ranked worse than
72.92% of 1418 companies
in the Biotechnology industry
Industry Median: -9.715 vs ATRA: -28.32

Atara Biotherapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -595.54%.


Atara Biotherapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Atara Biotherapeutics FCF Yield % Related Terms


Atara Biotherapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics FCF Yield % Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.00 -87.28 -355.76 -88.43 -38.45

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -319.85 -54.34 -37.89 -17.20 -30.53

ATRA vs RNTX, IBIO, OSTX: FCF Yield % Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's FCF Yield % falls into.


ATRA
31GF Score
Atara Biotherapeutics Inc ATRA
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Atara Biotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-50.94 / 132.49116
=-38.45%

Atara Biotherapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.073 * 4 / 40.26176
=-30.53%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -28.32 mean?
Atara Biotherapeutics (ATRA) has a FCF Yield % of -28.32 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Atara Biotherapeutics and its competitors. According to the industry distribution chart, Atara Biotherapeutics ranks #1034 out of 1418 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Atara Biotherapeutics' FCF Yield % too high?
Atara Biotherapeutics' current FCF Yield % is -28.32. Based on the distribution chart, Atara Biotherapeutics ranks #1034 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' FCF Yield % compare to RNTX and IBIO?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #1034 out of 1418 companies for FCF Yield %. This places Atara Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current FCF Yield % is -28.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.56, compared to a current price of $10.14 — trading 550% above its estimated fair value. The current FCF Yield % is -28.32. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current FCF Yield % is -28.32 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $10.14 is trading 550% above its estimated GF Value™ of $1.56. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • FCF Yield %: -28.32
  • GF Value™: $1.56 vs. price of $10.14 (550% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for ATRA

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.14
Price
$1.56
GF Value